Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. - Wikidata - awgldk - TriplyDB

Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.

Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.

http://www.wikidata.org/entity/Q30478736

about

Drug nanocrystals: A way toward scale-up Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization.Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments.

P2860

Q26744024-62375A44-B817-4F38-93CB-F1C0246176C4 Q34280372-626C8B41-0326-430C-BCCC-025321FE05ED Q44032375-C01662FE-6F08-48E8-8E48-6050C2D9E0B8

P2860

Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.

http://www.wikidata.org/entity/Q30478736

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Downscaling drug nanosuspensio ...... sicochemical characterization.

@ast

Downscaling drug nanosuspensio ...... sicochemical characterization.

@en

type

label

Downscaling drug nanosuspensio ...... sicochemical characterization.

@ast

Downscaling drug nanosuspensio ...... sicochemical characterization.

@en

prefLabel

Downscaling drug nanosuspensio ...... sicochemical characterization.

@ast

Downscaling drug nanosuspensio ...... sicochemical characterization.

@en

P1433

Q30478736-D2312605-6840-4A75-8D8A-05344ACC2F69

P1476

Q30478736-97CF7291-F61D-4425-8193-A9A080413984

P2093

Q30478736-61189B69-8143-4892-AB09-CEF84B63DA50

Q30478736-66717889-D28B-45D3-B882-0B3626B2EA0D

Q30478736-CD0CFB87-9539-41E5-B795-B4712A45769B

Q30478736-DB51BA33-9957-4D06-B731-8CE1A758CD14

Q30478736-EA6617F8-C08F-45A8-9AFD-7277A256329D

P2860

Q30478736-3482E79E-D58B-45E6-85E7-10ABDA273F15

Q30478736-3D793C05-3726-4F92-B60F-A2F4C715356E

Q30478736-5EA7D857-D9C2-46CF-ABB1-54E9E044FA20

Q30478736-6AB02A19-3B0D-4AD1-BF45-E45EC97E9222

Q30478736-79D83F42-A144-45E7-B40B-85DC3338EDE0

Q30478736-BC038472-D9E4-4618-8BDC-5CAF56AE93ED

Q30478736-C38BBB66-D7AB-446D-A80F-58B422888526

Q30478736-C3F702C4-FE73-4BBD-AD02-7BCC864D8C58

Q30478736-DA3F83D7-F3ED-4F1B-926C-B384AEF6C3E5

Q30478736-E983F320-F9D7-464D-BE0E-8F50B9F77D92

P2888

Q30478736-EAB9D48E-218C-4255-ADC3-833871410A74

P304

Q30478736-30203010-FC94-4534-8915-E2E2052F0574

P31

Q30478736-E51EE026-85BA-49EF-BD91-006CF2571C09

P356

Q30478736-24EEB6EB-C735-4124-85B6-44C86E7620E2

P407

Q30478736-BE7243B5-EABC-4B6C-AE16-722896AF8D01

P433

Q30478736-B052EE9B-B855-4293-81F9-E4C53647CA7A

P478

Q30478736-346AD157-D0A1-4623-A389-B69BE50E68B6

P50

Q30478736-04BD4A73-2F91-4C2E-92E0-49E09D61DB19

Q30478736-2DE28C13-900C-4FA5-B1C4-5C633F9B7DF6

P577

Q30478736-B2076A36-E150-406A-854D-519DD896A717

P5875

Q30478736-9438D108-501B-4011-820B-04BF176273F9

P6179

Q30478736-13CE1FC6-6D62-45AD-A620-95E9821D5E61

P698

Q30478736-2880D49E-3530-4136-8938-CEDE756B0D3E

P932

Q30478736-6D48F184-8B4E-4147-823B-0290284F1E45

P356

S12249-008-9170-5

P1433

AAPS PharmSciTech

P1476

Downscaling drug nanosuspensio ...... sicochemical characterization.

@en

P2093

Bernard Stuyven

http://www.w3.org/2001/XMLSchema#string

Bernard Van Eerdenbrugh

http://www.w3.org/2001/XMLSchema#string

Guy Van den Mooter

http://www.w3.org/2001/XMLSchema#string

Jan Van Humbeeck

http://www.w3.org/2001/XMLSchema#string

Ludo Froyen

http://www.w3.org/2001/XMLSchema#string

P2860

Improving drug solubility for oral delivery using solid dispersions.

Nanosuspensions: a promising drug delivery strategy.

Nanosuspensions in drug delivery.

Drugs as materials: valuing physical form in drug discovery.

Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.

Nanosizing--oral formulation development and biopharmaceutical evaluation.

Cyclodextrins as pharmaceutical solubilizers.

A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation.

Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing.

Critical freezing rate in freeze drying nanocrystal dispersions.

P2888

s12249-008-9170-5

P304

44-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12249-008-9170-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Johan A. Martens

Patrick F Augustijns

P577

2009-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23792654

http://www.w3.org/2001/XMLSchema#string

P6179

1003325829

http://www.w3.org/2001/XMLSchema#string

P698

19148764

http://www.w3.org/2001/XMLSchema#string

P932

2663663

http://www.w3.org/2001/XMLSchema#string